Medication info
Lometan Tablets 5/20 mg

Lometan Tablets 5/20 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
White, round film-coated tablets
Packaging
28 tablets/box [14 tablets/PTP×2]
Approval status
Active

MFDS item code 201405132 · Approved 2014.11.03 · Insurance code 671704370

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 mg. Since the maximum antihypertensive effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Section 2. Patients Who Should Not Take This Medicine under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in older adults.
Child dose
The safety and efficacy in pediatric patients under 18 years of age have not been established.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used for patients with essential hypertension who do not have sufficient blood pressure control with monotherapy of amlodipine or olmesartan medoxomil. It effectively lowers blood pressure and reduces the burden on the heart and blood vessels. This helps decrease the risk of complications and aids in stable management of blood pressure. It should be used appropriately depending on the patient's blood pressure control status to improve hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). It is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil) before administering this medicine; however, switching directly to this medicine may be considered if blood pressure is not controlled with monotherapy using the individual components. The maximum dose of this medicine is 10/40 mg. Since the maximum antihypertensive effect occurs within 2 weeks after administration, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Section 2. Patients Who Should Not Take This Medicine under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored more frequently and closely in older adults.

Child dose

The safety and efficacy in pediatric patients under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to the active ingredients or similar components, pregnant or nursing women, patients with severe liver impairment, severe aortic stenosis, biliary obstruction, patients on renal dialysis, patients in shock, certain diabetic patients, and patients with severe renal impairment should not be administered this medication. In patients with low blood pressure due to a lack of fluids or salts, careful monitoring is required when administering this medication for the first time, as symptoms of low blood pressure may occur, and appropriate action is needed in such cases. Since this medication has a vasodilatory effect, it should be administered with caution in patients with severe aortic stenosis, obstructive coronary artery disease, and congestive heart failure. It may affect kidney function, so patients with renal impairment or renal artery stenosis should be monitored closely. Since this medication is metabolized in the liver, caution is also needed when administering it to patients with liver impairment. During the use of this medication, adverse reactions such as dizziness, headache, hypotension, orthostatic hypotension, edema, dyspepsia, rash, etc. may occur, and if these symptoms are severe, consultation with a professional is necessary. It is generally advised not to use this medication during pregnancy, and if planning to become pregnant or currently pregnant, consultation with a doctor is essential. Nursing mothers are recommended to either discontinue breastfeeding or stop taking this medication, as it may cause adverse reactions in infants. Safety and efficacy of this medication have not been established in patients under 18 years of age, and it is not recommended for this group. In elderly patients, it is recommended to start at a low dose and monitor closely, considering the potential decline in renal and liver function. In case of overdose, symptoms such as hypotension and tachycardia may occur; therefore, seek appropriate treatment promptly by visiting the hospital. This medication should be stored in a tightly closed container, away from moisture, heat, and direct sunlight, in a location out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • sensory decline
  • syncope
Show 96 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • pollakiuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • dependent edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • systemic pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • alopecia
  • itching
  • autoimmune hepatitis
  • vomiting
  • angioedema
  • rhabdomyolysis
  • acute renal failure
  • elevated serum creatinine
  • alopecia
  • itching
  • urticaria
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

White, round film-coated tablets

Package unit

28 tablets/box [14 tablets/PTP×2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.